Sichuan Provincial People's Hospital
Chengdu, Sichuan, 610072, China
NCT Number: NCT06269432
1. Main objective: To explore the efficacy of precise antiplatelet therapy guided by platelet aggregation function in reducing the incidence of 30 day platelet hyperresponsiveness in patients with non-cardiogenic ischemic stroke. 2. Secondary objective: To explore the efficacy and safety of antiplatelet therapy in patients with non-cardiogenic ischemic stroke under the guidance of platelet aggregation function.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Chengdu, Sichuan, 610072, China
Non cardiac cerebral infarction accounts for more than 50% of cerebral infarction cases, and the key to its onset is increased platelet aggregation function. Aspirin and clopidogrel are Class A recommended drugs for the prevention and treatment of non cardiac cerebral infarction. However, after regular use of aspirin and clopidogrel, more than 30% of stroke patients still experience high on treatment platelet reactivity (HOPR) due to aspirin resistance and clopidogrel resistance, leading to stroke recurrence. Antiplatelet therapy is the cornerstone of the prevention and treatment of non cardiogenic cerebral infarction. Therefore, clinical research on the prevention and treatment of HOPR with antiplatelet therapy for non cardiogenic cerebral infarction is of great significance, which can help partially solve the bottleneck of resistance to antiplatelet therapy in cerebral infarction.Platelet aggregation function testing can timely detect antiplatelet therapy HOPR, guide drug adjustment, and is expected to become a testing standard for the prevention and treatment of antiplatelet therapy resistance.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
Time frame: 1-month
The incidence of HOPR at 30 ± 5days post-enrollment.
Time frame: 3-month
Including cardiovascular and cerebrovascular death, myocardial infarction, stroke, urgent revascularization, in-stent thrombosis, and bleeding events classified as BARC grade 2 or higher.
Sichuan Provincial People's Hospital
Other
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE
Acronym: PATH-STROKE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05416853
Arterial Occlusive Diseases, Brain Diseases
Hefei, Anhui, China
View Trial DetailsNCT07709806
Brain Diseases, Cardiovascular Diseases
Siping, Jilin, China
View Trial DetailsNCT07654582
Brain Diseases, Cardiovascular Diseases
Cairo, Egypt
View Trial DetailsNCT06049498
Brain Diseases, Cardiovascular Diseases
Beijing, China
View Trial Details